原启生物 - 成为创新驱动的全球领先，肿瘤免疫治疗新药的创制者
Oricell Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative and affordable immunotherapies for hematological malignancies and solid tumors. Its lead program, OriCAR-017, is a GPRC5D-targeting autologous CAR-T therapy for relapsed/refractory multiple myeloma with FDA and NMPA IND approvals. Oricell also advances Ori-C101, a GPC3-targeting CAR-T for hepatocellular carcinoma, leveraging its proprietary OriAb antibody library platform.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Dec 2025
Feb 2023
Aug 2022
Jan 2015
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
